JDRF Blog
FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a JDRF-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function in type 1 diabetes.
Read More About FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain individuals recently diagnosed with T1D.
Read More About Results Are Out: Tzield Benefits Newly Diagnosed Individuals
Top Type 1 Diabetes Advances of Fiscal Year 2023
JDRF highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Read More About Top Type 1 Diabetes Advances of Fiscal Year 2023
At ADA 2023, JDRF-Funded Research Takes Center Stage (with a “Happy Hour” by Dr. Aaron Kowalski)
JDRF joined thousands at the ADA's Scientific Sessions, where experts presented significant advancements in diabetes research and clinical trials.
Read More About At ADA 2023, JDRF-Funded Research Takes Center Stage (with a “Happy Hour” by Dr. Aaron Kowalski)Recent Articles
Sign up for our monthly Research Newsletter, The Pipeline, to stay up to date on the latest and greatest in T1D science.
By clicking Sign Up, I agree to the JDRF Privacy Policy. I also agree to receive emails from JDRF and I understand that I may opt out of JDRF subscriptions at any time.